Management of F3 Liver Disease with S3 Steatosis to Reduce Mortality

Risk Assessment and Monitoring

F3 fibrosis represents advanced fibrosis, which is an independent predictor of liver-related complications and mortality, according to the Clinical and Molecular Hepatology guidelines 1, 2
S3 steatosis in combination with advanced fibrosis significantly increases the risk of progression to cirrhosis and development of hepatocellular carcinoma (HCC), as stated by the Clinical and Molecular Hepatology guidelines 2
Regular monitoring for HCC is essential in patients with advanced fibrosis, with abdominal ultrasound being the primary surveillance method, recommended by the Clinical and Molecular Hepatology guidelines 2
For overweight or obese patients, CT or MRI should be considered for HCC surveillance, as suggested by the Clinical and Molecular Hepatology guidelines 2

Weight loss is the cornerstone of treatment for patients with F3 fibrosis and S3 steatosis, according to the Clinical and Molecular Hepatology and Diabetologia guidelines 1, 3
A gradual weight loss of less than 1 kg/week is recommended to avoid worsening portal inflammation and fibrosis, as stated by the Clinical and Molecular Hepatology guidelines 1
Specific weight loss targets include:
- ≥5% weight loss to reduce steatosis, recommended by the Diabetologia guidelines 3
- 7-10% weight loss to improve liver inflammation and steatohepatitis, suggested by the Diabetologia guidelines 3
- ≥10% weight loss to improve fibrosis and potentially achieve NASH remission, as stated by the Diabetologia guidelines 3
The American Heart Association recommends at least 150 minutes/week of moderate-intensity or 75 minutes/week of vigorous-intensity physical activity, as cited in the Diabetologia guidelines 3
The American Diabetes Association suggests physical activity should be tailored to the individual's preference and ability, as stated in the Diabetologia guidelines 3

The American Diabetes Association recommends medications with proven efficacy in NASH, such as GLP-1 receptor agonists, for patients with diabetes, as stated in the Gastroenterology guidelines 7, 8
The European Association for the Study of the Liver suggests avoiding sulfonylureas and insulin if possible, as they may increase the risk of HCC, as cited in the Clinical and Molecular Hepatology guidelines 2
The American Association for the Study of Liver Diseases recommends statins for patients with F3 fibrosis, as they are safe and associated with a 37% reduction in HCC risk and a 46% reduction in hepatic decompensation, as stated in the Gastroenterology guidelines 2, 7

The American Association for the Study of Liver Diseases suggests considering pharmacological treatment in addition to lifestyle modifications for patients with F3 fibrosis, as stated in the Clinical and Molecular Hepatology and Gastroenterology guidelines 1, 5
The European Association for the Study of the Liver recommends vitamin E to improve steatohepatitis in non-diabetic patients with NASH, as cited in the Gastroenterology guidelines 7

The American Association for the Study of Liver Diseases recommends implementing regular HCC surveillance with imaging every 6 months, as stated in the Clinical and Molecular Hepatology guidelines 2
Key preventive measures include smoking cessation, alcohol abstinence, weight loss, statin use when indicated, and optimal control of diabetes, preferably with GLP-1 receptor agonists, as recommended by the Clinical and Molecular Hepatology and Gastroenterology guidelines 2, 7, 8